Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma.

Alagpulinsa DA, Kumar S, Talluri S, Nanjappa P, Buon L, Chakraborty C, Samur MK, Szalat R, Shammas MA, Munshi NC.

Blood Adv. 2019 Dec 10;3(23):3968-3972. doi: 10.1182/bloodadvances.2019000181. No abstract available.

PMID:
31805191
2.

Alginate-microencapsulation of human stem cell-derived β cells with CXCL12 prolongs their survival and function in immunocompetent mice without systemic immunosuppression.

Alagpulinsa DA, Cao JJL, Driscoll RK, Sîrbulescu RF, Penson MFE, Sremac M, Engquist EN, Brauns TA, Markmann JF, Melton DA, Poznansky MC.

Am J Transplant. 2019 Jul;19(7):1930-1940. doi: 10.1111/ajt.15308. Epub 2019 Mar 25.

PMID:
30748094
3.

Harnessing CXCL12 signaling to protect and preserve functional β-cell mass and for cell replacement in type 1 diabetes.

Alagpulinsa DA, Cao JJL, Sobell D, Poznansky MC.

Pharmacol Ther. 2019 Jan;193:63-74. doi: 10.1016/j.pharmthera.2018.08.011. Epub 2018 Aug 24. Review.

PMID:
30149101
4.

A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.

Alagpulinsa DA, Ayyadevara S, Yaccoby S, Shmookler Reis RJ.

Mol Cancer Ther. 2016 Feb;15(2):241-50. doi: 10.1158/1535-7163.MCT-15-0660. Epub 2015 Dec 30.

5.

A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment.

Alagpulinsa DA, Yaccoby S, Ayyadevara S, Shmookler Reis RJ.

Cancer Biol Ther. 2015;16(6):976-86. doi: 10.1080/15384047.2015.1040951. Epub 2015 May 21.

6.

A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin.

Alagpulinsa DA, Ayyadevara S, Shmookler Reis RJ.

Front Oncol. 2014 Oct 30;4:289. doi: 10.3389/fonc.2014.00289. eCollection 2014.

Supplemental Content

Loading ...
Support Center